181 related articles for article (PubMed ID: 23613414)
21. [Infusion reactions].
Sato K; Kohgo Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1671-4. PubMed ID: 18931569
[TBL] [Abstract][Full Text] [Related]
22. Are antineoplastic drug acute hypersensitive reactions a submerged or an emergent problem? Experience of the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori.
Ferrari LA; Fanetti G; Rossi FG; Brambilla MC; Re B; Buzzoni R
Tumori; 2014; 100(1):9-14. PubMed ID: 24675484
[TBL] [Abstract][Full Text] [Related]
23. [Induction of allergic reactions by anticancer drugs in outpatient chemotherapy].
Matsuoka T; Yoshimura T; Asano H; Adachi S; Okada K; Yasuda T
Gan To Kagaku Ryoho; 2013 Feb; 40(2):209-14. PubMed ID: 23411957
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management.
Hewitt MR; Sun W
Clin Colorectal Cancer; 2006 Jul; 6(2):114-7. PubMed ID: 16945166
[TBL] [Abstract][Full Text] [Related]
25. Acute interstitial pneumopathy associated with docetaxel hypersensitivity.
Karacan O; Eyüboglu FO; Akçay S; Ozyilkan O
Onkologie; 2004 Dec; 27(6):563-5. PubMed ID: 15591716
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab: adverse event profile and recommendations for toxicity management.
Thomas M
Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844
[TBL] [Abstract][Full Text] [Related]
27. Assessment of symptom control in patients with cancer in Northwestern Turkey.
Kurt S; Unsar S
Eur J Oncol Nurs; 2011 Apr; 15(2):137-44. PubMed ID: 20832359
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin desensitization.
Choi J; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):137-41. PubMed ID: 15328672
[TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
Sendo T; Sakai N; Itoh Y; Ikesue H; Kobayashi H; Hirakawa T; Nakano H; Oishi R
Cancer Chemother Pharmacol; 2005 Jul; 56(1):91-6. PubMed ID: 15791461
[TBL] [Abstract][Full Text] [Related]
30. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
[TBL] [Abstract][Full Text] [Related]
31. Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.
Capelle H; Tummino C; Greillier L; Gouitaa M; Birnbaum J; Ausias N; Barlesi F; Montana M
J Clin Pharm Ther; 2018 Jun; 43(3):320-326. PubMed ID: 29092096
[TBL] [Abstract][Full Text] [Related]
32. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center.
Hansen NL; Chandiramani DV; Morse MA; Wei D; Hedrick NE; Hansen RA
J Oncol Pharm Pract; 2011 Jun; 17(2):125-30. PubMed ID: 20147576
[TBL] [Abstract][Full Text] [Related]
33. Incidence and severity of acute allergic-like reactions to i.v. nonionic iodinated contrast material in children.
Dillman JR; Strouse PJ; Ellis JH; Cohan RH; Jan SC
AJR Am J Roentgenol; 2007 Jun; 188(6):1643-7. PubMed ID: 17515388
[TBL] [Abstract][Full Text] [Related]
34. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH
Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
[TBL] [Abstract][Full Text] [Related]
35. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives.
Colwell HH; Mathias SD; Ngo NH; Gitlin M; Lu ZJ; Knoop T
J Infus Nurs; 2007; 30(3):153-60. PubMed ID: 17505216
[TBL] [Abstract][Full Text] [Related]
36. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
Maindrault-Goebel F; André T; Tournigand C; Louvet C; Perez-Staub N; Zeghib N; De Gramont A
Eur J Cancer; 2005 Oct; 41(15):2262-7. PubMed ID: 16154353
[TBL] [Abstract][Full Text] [Related]
37. Hypersensitivity reactions to chemotherapeutic drugs.
Shepherd GM
Clin Rev Allergy Immunol; 2003 Jun; 24(3):253-62. PubMed ID: 12721396
[TBL] [Abstract][Full Text] [Related]
38. Hypersensitivity Reactions to oxaliplatin: incidence and management.
Gowda A; Goel R; Berdzik J; Leichman CG; Javle M
Oncology (Williston Park); 2004 Nov; 18(13):1671-5; discussion 1676, 1680, 1683-4. PubMed ID: 15648298
[TBL] [Abstract][Full Text] [Related]
39. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
40. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients.
Walters BA; Van Wyck DB
Nephrol Dial Transplant; 2005 Jul; 20(7):1438-42. PubMed ID: 15840683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
